Have any questions or comments? Send us a message or email us here. We will get back to you soon.
Contact Us
REVOLUTIONIZING CANCER TREATMENT — We aim to reimagine and positively impact cancer management by using both our knowledge of cancer genomics and advanced technology capabilities. We partner with physicians to facilitate the best personalized treatment decisions for patients.
Ms. Chang was diagnosed with ovarian cancer at the age of 42, 18 years ago. She had almost accepted her fate, then her physician recommended Precision Medicine treatment. Ms. Chang shares how cancer genomic profiling has changed her life.
ACTHRD™ evaluates the use of PARP inhibitor for BRCA1/2 mutated or HRD positive patients.
ACTLung™ targets 13 common driver genes and assists newly diagnosed lung cancer patients to rapidly determine a first-line targeted therapy opportunity.
Going beyond diagnostics, ACT Genomics is committed to turning genomic data into actionable cancer solutions.
ACTOnco®+ analyzes >400 genes and 13 fusion genes to assist physicians identify the most suitable therapies. Treatment evaluations include targeted therapy, immunotherapy, hormone therapy, and chemotherapy.
ACTLiquid™ Pro is a comprehensive NGS-based liquid biopsy assay for pan-solid tumors covering 523 genes and 23 fusion gene variants in circulating tumor DNA. Treatment evaluations include targeted therapy, immunotherapy, and hormone therapy.
ACTDrug®+ is an NGS-based test, which sequences 40 druggable genes, 13 fusion genes, and more than 350 fusion transcripts simultaneously from cancer specimens.
ACTLung™ targets 13 common driver genes and assists newly diagnosed lung cancer patients to rapidly determine a first-line targeted therapy opportunity.
ACTFusion™ is a targeted, multi-biomarker assay that examines 13 druggable fusion genes, and more than 350 known and novel transcripts.
ACTBRCA® genetic tests detect mutations in BRCA1/2 genes, which can provide genetic information to evaluate whether a tumor is suitable for PARP inhibitors.
ACTHRD™ detects HRD status by LOH score and 24 HRR-related genes to evaluate whether a tumor is suitable for PARP inhibitors.
ACTMonitor®+ analyzes 50 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.
ACTMonitor® Lung analyzes 11 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.
ACTMonitor® Breast analyzes 8 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.
ACTMonitor® Colon analyzes 13 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.
ACTCerebra™ sequences 40 druggable genes to identify the most effective targeted therapies based on medical history.
ACTRisk™ hereditary gene testing decodes 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes, which provides additional information to a health management strategy.
ACTOnco®+ analyzes >400 genes and 13 fusion genes to assist physicians identify the most suitable therapies. Treatment evaluations include targeted therapy, immunotherapy, hormone therapy, and chemotherapy.
ACTLiquid™ Pro is a comprehensive NGS-based liquid biopsy assay for pan-solid tumors covering 523 genes and 23 fusion gene variants in circulating tumor DNA. Treatment evaluations include targeted therapy, immunotherapy, and hormone therapy.
ACTDrug®+ is an NGS-based test, which sequences 40 druggable genes, 13 fusion genes, and more than 350 fusion transcripts simultaneously from cancer specimens.
ACTLung™ targets 13 common driver genes and assists newly diagnosed lung cancer patients to rapidly determine a first-line targeted therapy opportunity.
ACTFusion™ is a targeted, multi-biomarker assay that examines 13 druggable fusion genes, and more than 350 known and novel transcripts.
ACTBRCA® genetic tests detect mutations in BRCA1/2 genes, which can provide genetic information to evaluate whether a tumor is suitable for PARP inhibitors.
ACTHRD™ detects HRD status by LOH score and 24 HRR-related genes to evaluate whether a tumor is suitable for PARP inhibitors.
ACTCerebra™ sequences 40 druggable genes to identify the most effective targeted therapies based on medical history.
ACTMonitor®+ analyzes 50 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.
ACTMonitor® Lung analyzes 11 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.
ACTMonitor® Breast analyzes 8 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.
ACTMonitor® Colon analyzes 13 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.
ACTRisk™ hereditary gene testing decodes 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes, which provides additional information to a health management strategy.
Have any questions or comments? Send us a message or email us here. We will get back to you soon.
Contact Us
